# First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Source: https://onco.cc/trials/nct06797999/  
OnCo record `nct06797999` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Antibody-drug conjugate (ADC) in sarcomas, run by Adcendo ApS, now recruiting.

## Summary

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma is a phase 1/2 interventional study registered as NCT06797999 by Adcendo ApS, with 270 participants planned, started 2025-06-05 and due to reach its primary completion in 2029-02-27. Interventions recorded: Antibody-drug conjugate (ADC).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06797999
- Phase: 1/2
- Setting: A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
- Sponsor: Adcendo ApS
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06797999: https://clinicaltrials.gov/study/NCT06797999

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06797999.json